BluMaiden Biosciences is an early-stage biotechnology platform company headquartered in Singapore. Their vision is to discover small molecules that cure diseases and these small molecules will be identified from human microbiomes (you may need to Google it). To do this, BluMaiden is integrating three areas: 1. Capturing data from family microbiomes. 2. Building a database to discover microbiome insights and 3. Creating a platform for more effective and efficient drug development. As BluMaiden was in the angel investor round of funding, there was very little to communicate the offer and articulate what made BluMaiden different and compelling from other biotech start-ups. Tangible helped bring BluMaiden’s vision to life through their brand promise, brand architecture and visual and verbal communications system. This ensured the brand was relevant to both biotechnology partners and potential investors.
Tangible developed a new brand identity for BluMaiden to reflect how the business brings together three capabilities for small molecules drug discovery. Tangible then developed the visual and verbal language for the brand and a full suite of applications to communicate with the medical and investment communities. Tangible also designed and built both an interim and full website for BluMaiden.
Tangible helped conceptualize and model the brand architecture to reflect the small molecule drug discovery value chain. Family microbiome capture became ‘BabyPass’, the database for microbiome insights became ‘Daisy’ and the platform for more effective drug discovery was named ‘Maiden’. Collectively they illustrate the BluMaiden biotech branding offer. As BabyPass is a consumer-facing brand this has been developed as an unendorsed sub-brand.
Tangible developed a booth for biotech trade shows to ensure the brand is consistently represented at promotional events.